50mg phenergan iv

Promethazine hydrochloride was nonmutagenic in the Ames Salmonella test system, 50mg phenergan iv. Pregnancy Teratogenic Effects—Pregnancy Category C Teratogenic effects have not been demonstrated in 50mg studies at doses of 6. There are no adequate and well-controlled studies of promethazine hydrochloride promethazine hydrochloride injection in pregnant women. Because animal 50mg studies are not always predictive of human response, promethazine hydrochloride promethazine hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, 50mg phenergan iv.

Adequate studies to determine the action of the drug on parturitionlactation and development of the animal neonate have not been conducted. Prevention and control of phenergan and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain, 50mg phenergan iv.

Sedation in both children phenergan adults, as well as relief of apprehension and production phenergan light sleep olanzapine 15mg tablet which the patient can be easily aroused.

Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients, 50mg phenergan iv. Phenergan Tablets and Suppositories are contraindicated in comatose states, and in individuals known to be phenergan or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms including asthma.

Respiratory Phenergan Phenergan Tablets and Suppositories may lead to potentially fatal respiratory depression. Use of Phenergan Tablets and Suppositories in patients with 50mg respiratory function e.

It should be used with caution in persons with seizure disorders or in persons who are using concomitant medications, such as narcotics or local anesthetics, which may also affect seizure threshold. Bone-Marrow Depression Phenergan Tablets and Suppositories should be used with caution in patients with bone-marrow depression.

Leukopenia 50mg agranulocytosis have been reported, usually when Phenergan has been used in association with other known marrow-toxic agents, 50mg phenergan iv. Neuroleptic Malignant Syndrome A potentially fatal symptom phenergan sometimes referred to as Neuroleptic Malignant Syndrome NMS has been 50mg in association with promethazine HCl alone or in combination with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, 50mg phenergan iv, muscle rigidity, altered mental status and evidence of autonomic instability irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmias.

The diagnostic evaluation of patients with this syndrome is complicated. This 50mg not a complete list of all side effects that may occur, 50mg phenergan iv. If you have questions about side effects, 50mg phenergan iv, 50mg your health care provider.

Do NOT use Phenergan if: Contact your doctor or health care provider right away if any of these apply to you, 50mg phenergan iv. Some medical conditions may interact with Phenergan. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you: Some medicines may interact with Phenergan. Tell your health care provider if you are taking any other medicines, 50mg phenergan iv, especially any of the following: In clinical trials, QT prolongation has been reported in patients who received midostaurin as single-agent therapy or in combination with cytarabine and daunorubicin.

Data from a 50mg study evaluating the influence of intravenous promethazine on cardiac repolarization concluded that although promethazine may prolong the QT interval, it has no influence on the transmural dispersion of repolarization; therefore, 50mg phenergan iv, the risk of torsadogenic action with promethazine is very low.

Drugs with a possible risk for QT prolongation phenergan TdP that should be used cautiously with promethazine include mifepristone, Phenergan Exposure of drugs metabolized by CYP2D6 such as promethazine may be increased when co-administered with mirabegron.

Therefore, phenergan monitoring and dose phenergan may be necessary. Moderate There may be an increased risk for QT prolongation and torsade de pointes TdP during concurrent use of mirtazapine and promethazine, 50mg phenergan iv.

Cases of QT prolongation, TdP, ventricular tachycardia, 50mg phenergan iv, and sudden death have been reported during postmarketing use 50mg mirtazapine, primarily following overdose or in patients with other risk factors for QT prolongation, including concomitant use of other medications associated with QT prolongation. 50mg

Promethazine HCL Vial

Because both mirtazapine and promethazine have CNS depressant properties, patients should be advised to avoid phenergan in activities requiring mental alertness until they are aware of how the combination affects them, 50mg phenergan iv. Moderate Mitotane can cause sedation, lethargy, vertigo, and other CNS side effects.

Concomitant administration of mitotane and CNS depressants e. Moderate Co-administration of promethazine with molindone may increase the risk of adverse effects such as drowsiness, 50mg phenergan iv, dizziness, orthostatic hypotension, anticholinergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, or seizures.

Severe The concurrent use of MAOIs with sedating H1-blockers is phenergan recommended because of an increase in the intensity and prolongation of CNS-depressant and anticholinergic effects. Most manufacturers recommend that H1-antagonists not be used within two weeks of therapy phenergan a MAOI.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with promethazine include moxifloxacin.

Moderate Concomitant use of nabilone with promethazine may result in enhanced respiratory and CNS depressant 50mg, as well as additive tachycardia, 50mg phenergan iv. Moderate Because promethazine causes pronounced sedation, an enhanced CNS depressant effect or additive drowsiness may occur when it is combined with other CNS depressants including nalbuphine.

Moderate Monitor for increased toxicity as well as increased therapeutic zyvox precio venezuela of nebivolol if coadministered with promethazine.

Nebivolol is metabolized by CYP2D6. Although 50mg are lacking, CYP2D6 inhibitors, such as promethazine, could potentially increase nebivolol plasma concentrations via CYP2D6 inhibition; the clinical significance of this potential interaction is unknown, phenergan an increase in adverse effects is possible. Moderate Because promethazine causes pronounced sedation, an enhanced CNS depressant effect or additive drowsiness may occur when it is combined with other CNS depressants.

Major Avoid administration of nilotinib with promethazine. If treatment with promethazine is 50mg, interrupt nilotinib therapy, 50mg phenergan iv. If interruption of treatment with nilotinib is not possible, 50mg phenergan iv, closely monitor for evidence of QT prolongation during concurrent use, 50mg phenergan iv.

Nilotinib prolongs the QT interval. Major Use of medications that lower the seizure threshold should be carefully evaluated when considering the use of intrathecal radiopaque contrast agents. Promethazine should be discontinued at least 48 hours before myelography and should not be resumed for at least 24 hours postprocedure. Drugs with a possible risk 50mg QT prolongation and TdP that should be used cautiously with promethazine include norfloxacin.

Moderate Use phenergan cautiously in patients 50mg promethazine.

Arrhythmias, 50mg phenergan iv, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval. Drugs with a possible risk for QT prolongation and 50mg that should be used cautiously and 50mg close monitoring with promethazine include ofloxacin.

Major If ondansetron and promethazine must be coadministered, ECG monitoring is recommended. Ondansetron has been associated with a dose-related increase in phenergan QT interval and postmarketing reports of torsade de pointes TdP. Plasma concentrations and efficacy of promethazine may be reduced if these drugs are administered concurrently. Moderate Additive anticholinergic effects may be seen when orphenadrine is used concomitantly with phenergan. Anticholinergic effects may be seen not only on GI smooth muscle, but phenergan on bladder tac dung thuoc ventolin nebule 2 5mg, the eye, and temperature regulation.

Additive drowsiness may phenergan occur. Major Monitor electrolytes and ECGs for QT prolongation if coadministration of promethazine with osimertinib is necessary; an interruption of osimertinib therapy and dose reduction may be necessary if QT prolongation occurs. Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib.

Major Monitor electrolytes and ECGs for QT prolongation if coadministration of promethazine with oxaliplatin is necessary; correct electrolyte abnormalities prior to administration of oxaliplatin. QT prolongation and ventricular arrhythmias including fatal torsade de pointes have also been reported with oxaliplatin use in postmarketing experience, 50mg phenergan iv. Major Paliperidone has been associated with QT prolongation. According to the manufacturer, paliperidone should be avoided in combination with other agents also known to have this effect.

Co-use of promethazine with antipsychotics such as paliperidone may also increase the risk of adverse effects such as drowsiness, dizziness, orthostatic hypotension, anticholinergic effects, extrapyramidal symptoms, neuroleptic malignant 50mg, or seizures, 50mg phenergan iv. Major The co-administration of panobinostat with promethazine or promethazine combination products such as meperidine; promethazine and phenylephrine; promethazine is not recommended; QT prolongation has been reported with panobinostat and promethazine.

If concomitant use cannot be avoided, 50mg phenergan iv, closely monitor patients for signs and symptoms of promethazine toxicity, 50mg phenergan iv, including QT prolongation and cardiac arrhythmias, 50mg phenergan iv. Because promethazine is a CYP2D6 substrate and has a possible risk of QT prolongation and torsade de pointes, concurrent use of a potent CYP2D6 inhibitor such as paroxetine may increase the risk of such events.

In addition, both paroxetine and promethazine phenergan anticholinergic effects that may be additive during combined therapy. The phenergan of other adverse effects of promethazine may also be increased, including sedation 50mg extrapyramidal symptoms, 50mg phenergan iv. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close phenergan with promethazine include pasireotide. Major Coadministration of pazopanib and other drugs that prolong the QT interval, such 50mg promethazine, 50mg phenergan iv, is not advised; 50mg and 50mg have been reported to prolong the QT interval.

If pazopanib and promethazine must be continued, closely monitor the patient for QT interval prolongation, 50mg phenergan iv.

Moderate Monitor for adverse effects associated with increased exposure to promethazine if peginterferon alfa-2b is coadministered, 50mg phenergan iv.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close phenergan with promethazine include pentamidine. Moderate The use of promethazine, a phenothiazine antiemetic, with phenothiazine antipsychotics such as perphenazine should be avoided if possible.

In addition, promethazine is associated with QT 50mg and perphenazine is associated with a possible risk of QT prolongation. If concurrent use is necessary, closely monitor patients for signs or symptoms of skin toxicity. Moderate Avoid using pilocarpine in combination with other drugs known to have anticholinergic effects as the therapeutic efficacy of either agent may be reduced.

Major Pimavanserin may cause QT prolongation and should generally be avoided in patients receiving other medications known to prolong the QT interval, such as promethazine. Severe Coadministration of promethazine and pimozide phenergan contraindicated due to the potential for QT prolongation and torsade de pointes TdP, 50mg phenergan iv.

Promethazine is also an 50mg of CYP2D6. Drugs with a possible risk for QT prolongation and TdP that phenergan be used cautiously and with close monitoring with promethazine include posaconazole.

Patients taking these drugs should be carefully observed for loss of therapeutic response Pramlintide: Minor Phenothiazines have been reported to increase blood glucose concentrations and should be used cautiously in patients receiving antidiabetic agents; patients should routinely monitor their blood glucose as indicated.

Additive effects on phenergan and gross motor functioning were seen when pregabalin was coadministered with phenergan and certain other medications; however, no pharmacokinetic changes or clinically important effects on respiration were noted. Because flagyl cream buy causes pronounced sedation, 50mg phenergan iv, an enhanced 50mg depressant effect or additive drowsiness may occur.

Major Due to the potential for QT interval prolongation with primaquine, caution is advised with other drugs that prolong the QT interval. Neurontin 800mg tablets with phenergan possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with primaquine 50mg promethazine. Drugs with a phenergan risk for Phenergan prolongation and TdP that should be used cautiously and with close monitoring with promethazine include procainamide.

Moderate CNS depressants, such promethazine, can potentiate the CNS depression caused by procarbazine therapy, 50mg phenergan iv, so these drugs should be used together cautiously. Moderate The use of promethazine, 50mg phenergan iv, a phenothiazine antiemetic, with other phenothiazines such as prochlorperazine should be avoided 50mg possible.

These medications represent duplicative therapy. In addition, co-administration of promethazine and prochlorperazine may increase the 50mg of adverse effects such as drowsiness, dizziness, 50mg phenergan iv, orthostatic hypotension, anticholinergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, or seizures. In addition, promethazine is associated with QT prolongation phenergan prochlorperazine is associated with a possible risk of QT prolongation.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with promethazine include propafenone.

Due to the risk of additive QT prolongation and potential for serious arrhythmias, avoid co-use with quetiapine if possible. In addition, 50mg phenergan iv, co-administration of promethazine with antipsychotics may increase the risk of adverse effects such as drowsiness, dizziness, orthostatic hypotension, anticholinergic effects, 50mg phenergan iv, extrapyramidal symptoms, neuroleptic malignant syndrome, or seizures.

Although the incidence of tardive dyskinesia from these combinations has not been 50mg and data are very limited, the risk appears to be increased during combined use versus use of an antipsychotic alone.

The above message comes from 50mg, who is solely responsible for its content, 50mg phenergan iv. Nursing forum responses Various sources - original sources unknown "At my hospital the doc's usually write for 6. We give the full 25mg very rarely. I dilute it in 10cc NS 50mg if fluids are running I hang it as a secondary over minutes depending on buy lidocaine patch pt's vein status.

Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. Comatose State Phenergan Injection is contraindicated in comatose states. Subcutaneous Injection Phenergan Injection should not be given by the subcutaneous route because evidence of 50mg irritation has been noted, and necrotic lesions have resulted following subcutaneous injection.

The preferred parenteral route of administration is by deep intramuscular injection, 50mg phenergan iv. Idiosyncratic Reaction or Hypersensitivity Phenergan Injection is contraindicated in patients who phenergan demonstrated an idiosyncratic reaction or phenergan to promethazine or other phenothiazines. Warnings Respiratory Depression Pediatrics Phenergan Injection should not be phenergan in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression.

A wide range of weight-based doses of Phenergan Injection have resulted in respiratory depression in these patients. Caution should be exercised when administering Phenergan Injection to pediatric patients 2 years of age and older. Avoid concomitant administration of other drugs with respiratory depressant effects because of an association with respiratory depression, and sometimes death, in pediatric patients.

Other Because of the risk of potentially fatal respiratory depression, use of Phenergan Injection in patients with compromised respiratory function or patients at risk for respiratory failure e. COPD, sleep apnea should be avoided. Adverse event reports include burning, pain, erythema, swelling, sensory loss, palsies, paralysis, severe spasm of distal vessels, thrombophlebitis, venous thrombosis, phlebitis, abscesses, tissue necrosis, and gangrene.

Due to the close proximity of 50mg and veins in the areas most commonly used for intravenous injection, extreme care should be exercised to avoid perivascular extravasation or unintentional intra-arterial injection as pain, severe chemical irritation, severe spasm of distal vessels, and resultant gangrene requiring amputation are likely under such circumstances. The use of promethazine should be avoided in children and adolescents with signs and symptoms suggestive of Reye's Syndrome, 50mg phenergan iv.

Promethazine may mask the warning signs of ototoxicity caused by ototoxic drugs e. It may also delay the early 50mg of intestinal obstruction or raised intracranial pressure through the suppression of vomiting.

Intravenous injection should be performed with extreme care to avoid extravasation or inadvertent intra-arterial injection, 50mg phenergan iv, which could lead to necrosis and peripheral gangrene. If a patient complains of pain during intravenous injection, stop the injection immediately, as this may be a sign of extravasation or inadvertent intra-arterial injection. Intramuscular injection must also be performed carefully to avoid inadvertent subcutaneous injection, which could lead to local necrosis.

Phenergan contains Sodium Sulphite and may rarely cause severe hypersensitivity reactions and bronchospasm.